These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 30129144)

  • 1. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
    Papageorgiou SG; Kontos CK; Kotsianidis I; Vasilatou D; Symeonidis A; Galanopoulos A; Bouchla A; Hatzimichael E; Repousis P; Zikos P; Viniou NA; Poulakidas E; Vassilakopoulos TP; Diamantopoulos P; Diamantopoulos MA; Mparmparousi D; Bouronikou E; Papadaki H; Panayiotidis P; Pappa V
    Hematol Oncol; 2018 Oct; 36(4):693-700. PubMed ID: 30129144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
    Pleyer L; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl-Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Geissler D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
    J Hematol Oncol; 2016 Apr; 9():39. PubMed ID: 27084507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
    Donnette M; Hamimed M; Ciccolini J; Sicard G; Correard F; Farnault L; Ouafik L; Venton G; Fanciullino R
    Br J Haematol; 2023 Nov; 203(4):625-636. PubMed ID: 37691342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study.
    Saga T; Kanagawa M; Harada T; Lang L; Yamawaki F; Ishihara T
    Intern Med; 2024 Mar; 63(6):781-790. PubMed ID: 37495538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Pasvolsky O; Saliba RM; Popat UR; Alousi A; Mehta R; Yeh J; Al-Atrash G; Adeel M; Ramdial J; Marin D; Rondon G; Kebriaei P; Champlin R; Daver N; Dinardo C; Short NJ; Shpall EJ; Oran B
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e196-e204. PubMed ID: 38403505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse.
    Ueda M; El-Jurdi N; Cooper B; Caimi P; Baer L; Kolk M; Brister L; Wald DN; Otegbeye F; Lazarus HM; Sandmaier BM; William B; Saunthararajah Y; Woost P; Jacobberger JW; de Lima M
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1122-1127. PubMed ID: 30599207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
    Jabbour E; Kantarjian H; O'Brien S; Kadia T; Malik A; Welch MA; Teng A; Cortes J; Ravandi F; Garcia-Manero G
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):592-6. PubMed ID: 23790798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
    Zeidan AM; Lee JW; Prebet T; Greenberg P; Sun Z; Juckett M; Smith MR; Paietta E; Gabrilove J; Erba HP; Tallman MS; Gore SD;
    Br J Haematol; 2014 Aug; 166(3):352-9. PubMed ID: 24712482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine.
    Ogawa S; Sakamoto T; Matsuoka R; Ishitsuka K; Ogino Y; Sootome A; Makishima K; Yoshida C; Ito Y; Shimizu S; Suyama T; Shinagawa A; Ito T; Obara N; Kusakabe M; Sakata-Yanagimoto M; Miyazaki Y; Nannya Y; Chiba S
    Cancer Rep (Hoboken); 2024 Jan; 7(1):e1938. PubMed ID: 38014499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.
    Kazachenka A; Young GR; Attig J; Kordella C; Lamprianidou E; Zoulia E; Vrachiolias G; Papoutselis M; Bernard E; Papaemmanuil E; Kotsianidis I; Kassiotis G
    Genome Med; 2019 Dec; 11(1):86. PubMed ID: 31870430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes.
    Matsumoto T; Murakami Y; Yoshida-Sakai N; Katsuchi D; Kanazawa K; Okamura T; Imamura Y; Ono M; Kuwano M
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia.
    Garcia-Manero G; Almeida A; Giagounidis A; Platzbecker U; Garcia R; Voso MT; Larsen SR; Valcarcel D; Silverman LR; Skikne B; Santini V
    BMC Hematol; 2016; 16():12. PubMed ID: 27148452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial.
    Holmberg-Thydén S; Dufva IH; Gang AO; Breinholt MF; Schejbel L; Andersen MK; Kadivar M; Svane IM; Grønbæk K; Hadrup SR; El Fassi D
    Cancer Immunol Immunother; 2022 Feb; 71(2):433-444. PubMed ID: 34218294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
    Rajakumaraswamy N; Gandhi M; Wei AH; Sallman DA; Daver NG; Mo S; Iqbal S; Karalliyadda R; Chen M; Wang Y; Vyas P
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):260-268.e2. PubMed ID: 38216397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HALP score as a novel prognostic factor for patients with myelodysplastic syndromes.
    Gursoy V; Sadri S; Kucukelyas HD; Hunutlu FC; Pinar IE; Yegen ZS; Alkış N; Ersal T; Ali R; Ozkocaman V; Ozkalemkas F
    Sci Rep; 2024 Jun; 14(1):13843. PubMed ID: 38879594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine-A Retrospective Analysis.
    Wiśniewski K; Pruszczyk-Matusiak K; Puła B; Lech-Marańda E; Góra-Tybor J
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflamma-miRs Profile in Myelodysplastic Syndrome Patients.
    Montes P; Rusanova I; Cornejo E; García P; Guerra-Librero A; López MDS; Haro T; Escames G; Acuña-Castroviejo D
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928489
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Riabov V; Xu Q; Schmitt N; Streuer A; Ge G; Bolanos L; Wunderlich M; Jann JC; Wein A; Altrock E; Demmerle M; Mukherjee S; Ali AM; Rapp F; Nowak V; Weimer N; Obländer J; Palme I; Göl M; Jawhar A; Darwich A; Wuchter P; Weiss C; Raza A; Foulks JM; Starczynowski DT; Yang FC; Metzgeroth G; Steiner L; Jawhar M; Hofmann WK; Nowak D
    Haematologica; 2024 May; 109(5):1426-1438. PubMed ID: 37916386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine.
    Takada E; Nakamura N; Kaneda Y; Fukuno K; Lee S; Fujita K; Morishita T; Ikoma Y; Matsumoto T; Nakamura H; Kitagawa J; Kanemura N; Kasahara S; Hara T; Tsurumi H; Shimizu M
    Hematol Rep; 2024 Feb; 16(1):114-124. PubMed ID: 38534882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System.
    Inoue Y; Okamoto H; Miyashita A; Kawaji-Kanayama Y; Chinen S; Fujino T; Tsukamoto T; Shimura Y; Mizutani S; Kaneko H; Kuwahara-Ota S; Fuchida SI; Nishiyama D; Hirakawa K; Uchiyama H; Uoshima N; Kawata E; Kuroda J
    Oncol Lett; 2024 Feb; 27(2):62. PubMed ID: 38192677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.